CLINDETS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINDETS (CLINDETS).
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It also acts as a competitive inhibitor of bacterial ribosomal RNA methyltransferases.
| Metabolism | Hepatic metabolism primarily via CYP3A4 to active and inactive metabolites; some metabolites (N-demethyl, sulfoxide) have antibacterial activity. |
| Excretion | Approximately 10% of the dose is excreted unchanged in urine; the remainder is hepatically metabolized and eliminated via bile (fecal: ~40%) and urine as inactive metabolites. |
| Half-life | Terminal elimination half-life is 2.4-3 hours in adults; prolonged to 4-6 hours in severe hepatic impairment. |
| Protein binding | Clindamycin is 90-94% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is approximately 0.6-0.8 L/kg, indicating extensive tissue penetration including skin and bone. |
| Bioavailability | Topical gel: approximately 5-10% systemically absorbed; vaginal cream: ~4% absorbed; oral: ~90% (not relevant for this formulation). |
| Onset of Action | Topical: Clinical improvement may be noted within 2-6 weeks of regular application; vaginal cream: symptom relief begins within 1-3 days. |
| Duration of Action | The pharmacodynamic effect persists for 8-12 hours after topical application, supporting twice-daily dosing; systemic dosing not applicable. |
| Molecular Weight | 470.6 |
Clindamycin: 150-450 mg orally every 6 hours; 600-900 mg IV every 8 hours. Max: 1.8 g/day for severe infections.
| Dosage form | SWAB |
| Renal impairment | No dose adjustment required for GFR >30 mL/min. For GFR 10-29 mL/min: no adjustment; for GFR <10 mL/min: no adjustment, but consider prolonging interval to every 12 hours if toxicity. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or use normal dose but monitor. Child-Pugh C: use with caution, reduce dose by 75% or avoid if severe impairment. |
| Pediatric use | Neonates: 5-10 mg/kg IV every 12 hours; Infants/Children: 10-40 mg/kg/day orally in 3-4 divided doses; IV: 20-40 mg/kg/day in 3-4 divided doses. Max: 1.8 g/day. |
| Geriatric use | Use with caution due to higher risk of C. difficile colitis. Dose reduction not required unless renal/hepatic impairment. Monitor renal function and adjust accordingly. |
| 1st trimester | Contraindicated due to known teratogenic effects (cleft palate, cardiovascular malformations). |
| 2nd trimester | Contraindicated; associated with fetal adrenal suppression and androgenization of female fetuses. |
| 3rd trimester | Contraindicated; risk of neonatal adrenal insufficiency and potential for premature closure of ductus arteriosus. |
Clinical note
Comprehensive clinical and safety monograph for CLINDETS (CLINDETS).
| Placental transfer | Crosses placenta extensively; metabolized to active form; fetal concentrations can reach 25-50% of maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; however, due to the potential for adverse effects on infant adrenal function and bone growth, use during breastfeeding is not recommended. Alternative therapies should be considered. |
■ FDA Black Box Warning
Clindamycin can cause severe and potentially fatal colitis, including pseudomembranous colitis (Clostridioides difficile-associated diarrhea).
| Serious Effects |
Systemic fungal infectionKnown hypersensitivity to clindamycin or any componentPregnancy (except for specific life-threatening conditions where benefit outweighs risk)
| Precautions | May cause severe colitis (including pseudomembranous colitis). Overgrowth of non-susceptible organisms (e.g., fungi). Prolonged use may result in superinfection. Use with caution in patients with gastrointestinal disease, hepatic impairment, or atopic history. |
| Food/Dietary | No direct food interactions. Oral formulations should be taken with full glass of water; separate from dairy products by 2 hours due to decreased absorption. For topical vaginal, no dietary restrictions. |
Loading safety data…
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | FDA pregnancy category D. First trimester: Avoid due to potential teratogenic effects (cleft palate, cardiac defects) based on animal studies and limited human data. Second and third trimesters: Use only if clearly needed; may cause fetal harm including premature closure of ductus arteriosus and oligohydramnios. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and fetal ultrasound for signs of ductus arteriosus constriction or oligohydramnios. Assess fetal growth and amniotic fluid volume regularly during prolonged use. |
| Fertility Effects | Limited data; no known direct effect on fertility. However, use of NSAIDs including CLINDETS may impair female fertility via reversible inhibition of ovulation. Discontinuation may restore ovulation. |
| Clinical Pearls | Clindets is clindamycin 1% in a hydroalcoholic vehicle. Avoid contact with eyes and mucous membranes. For vaginal use only; if accidental eye exposure occurs, rinse with copious water. Associated with pseudomembranous colitis; discontinue if diarrhea occurs. In pregnancy, risk factor B; only use if clearly needed. |
| Patient Advice | Use only as directed; typically twice daily for 3-7 days. · Do not use during menstruation or other vaginal products. · If you miss a dose, apply as soon as remembered unless near next dose. · Wash hands before and after application. · Report severe abdominal cramps or watery diarrhea immediately. · Do not use if allergic to clindamycin or lincomycin. |